This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

Inclusion criteria: * ≥ 18 years at screening. * Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. * Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial * Currently taking dabigatran etexilate * They meet the following criteria: * Group A: Overt bleeding judged by the physician to require a reversal agent. OR * Group B: A condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours. Exclusion criteria: Group A: * Patients with minor bleeding (e.g. epistaxis, hematuria) who can be managed with standard supportive care. * Patients with no clinical signs of bleeding. * Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol). Group B: * A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low. * Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose…